Effective Therapeutic Development Starts with Vector Design: The Smart Cookie Guide
Keywords: Therapeutic development, cell and gene therapy, vector design
It’s taken years of long workdays, countless weekends, and unspeakable stress-induced hair loss, but you’ve identified and confirmed the gene that will effectively treat a disease. Surely the hardest part is over?
Then reality sets in and the next challenge begins: turning your scientific breakthrough into a therapy ready to change patients' lives. The therapeutic not only has to be proven safe and effective in patients, but also practical in terms of production and costs.
Figure 1. Key phases of drug development and their major challenges.
The next phases of development (Figure 1) require optimizing drug efficacy and scalability while meeting regulatory guidelines and ensuring Good Manufacturing Practice (GMP)-compliant, consistent manufacturing. Since every therapeutic is unique, cell and gene therapy (CGT) development isn’t cookie-cutter; each product requires tailored, rigorous process development for optimal results. However, most researchers rely on multiple contractors across the development pipeline, resulting in a fragmented approach that introduces handoff inefficiencies, knowledge loss during tech transfer, and misalignment between early development decisions and downstream manufacturing requirements. At VectorBuilder, we offer a more comprehensive solution. Our unique, integrated approach provides solutions that start from discovery and vector design, ensuring your fundamental R&D choices are forward-thinking, positioning your vector products for successful drug development, and effectively eliminating any gaps that exist before most CDMOs engage (Figure 2).
Figure 2. VectorBuilder’s expertise spans the full drug development pipeline, from concept all the way to commercial manufacturing.
Let’s talk about Good Vector Practice (GVP) and CliniVec™
A whopping 90% of CGT drug candidates fail at clinical trials. Additionally, based on data released by the US Food and Drug Administration (FDA), 74% of CGT rejections between 2020 and 2024 were due to quality and/or manufacturing deficiencies – essentially gaps in CMC. As a consequence of these failures, developers are forced into a costly loop, triggering (often significant) vector and process redesigns, new validations, and additional comparability studies, thereby leading to extensive setbacks, increased costs, and delays in patient access to potential treatment. Critically, most of these failures stem from poor design and development decisions early in the pipeline and can be mitigated by aligning early vector design and production choices with future scale-up and commercial feasibility. It may feel premature to plan this early, but the high number of FDA rejections underscores that alignment isn’t optional but essential for streamlined, successful development.
Hence, we propose Good Vector Practice (GVP), a framework encompassing every phase of a vector’s lifecycle, from initial design and cloning through in-process and product quality control to long-term vector banking, ensuring quality and longevity throughout. Once thought relevant only to efficacy, emerging CMC data from the past decade reveal that vector design also critically influences scale-up and process development. To help developers apply these principles in practice, VectorBuilder offers the free and personalized CliniVec™ consultation service. The service supports early-stage optimization of vector design and production workflows for progress to commercialization, keeping efficacy, safety, and manufacturability at the forefront to facilitate a smoother path to clinical application (Figure 3). Our expertise has already been applied to a variety of cases to improve outcomes in each of these primary pillars.
Figure 3. The CliniVec™ development approach utilizes intelligent vector design and prioritizes GVP to maximize efficacy, safety, and manufacturability throughout the entire development pipeline to ensure they meet the ever-changing requirements of preclinical and clinical studies. This approach strikes the right balance between the shortest path to clinic and long-term product viability, ultimately saving time and costs.
-
Engineering efficacy
Designing a CGT vector is similar to perfecting a cookie recipe, where every ingredient (vector component) plays a role. In this context, every component must perform a specific function, interact appropriately with other components, and comply with regulations to enter the human body.
In order to design a suitably potent and stable vector, researchers must carefully optimize multiple factors, including the choice of vector system (e.g., viral, transposon, or IVT RNA), backbone type (e.g., high-copy, low-copy, or miniaturized), antibiotic selection marker (e.g., ampicillin, kanamycin, or none), essential biological components (e.g., promoters, linkers, spacers, polyadenylation signals, and enhancers), and codon optimization. Figure 4 demonstrates how optimization of promoter and ORF sequences in an AAV transfer vector can greatly impact therapeutic efficacy. This principle applies to all aspects of gene therapy vectors, necessitating that optimal components be determined uniquely for each specific application.
Figure 4. Optimization of vector components significantly improves overall therapeutic efficacy. (A) Survival rates of transgenic knockout mice treated with different sequence versions of the promoter driving GOI in the AAV9-based treatment of a genetic disorder. Treated control wild-type (WT) and non-treated control (NC) mutant mice were also observed. (B) Optimizing ORFs, in this case via truncation, can improve therapeutic efficacy. NC= negative control (non-treated KO mice), PC= positive control mice that were treated with a reference vector from publications.
As we’ve previously reported, it is estimated that ~45-50% of lab-made plasmids have hidden or undetected design and/or sequence errors that could compromise their intended applications. Adding to the complexity, numerous unvalidated versions of components exist in the gene delivery community. For instance, multiple versions of the common CMV promoter with various lengths and sequences have been reported. Differences among these components and constructs can affect transcriptional activity, with downstream consequences for therapeutic efficacy, scalable manufacturing, and regulatory compliance. Furthermore, switching CMV variants mid-development, for instance to enhance manufacturability, is generally considered a major CMC change, which potentially requiring additional comparability data or even new regulatory submissions. This makes it essential to thoroughly validate individual components or use tools like our Vector Design Studio, which incorporates a comprehensive library of verified components and validated design algorithms to generate reliable, optimized vector designs for discovery that can be transitioned smoothly to preclinical and clinical studies. Ultimately, early-stage vector design should be treated as an iterative process, guided by experimental results and refined over time to ensure success.
-
Design for scale-up
So you’ve perfected your cookie recipe, but now what? Rationally, the cookies can't be mass-marketed by baking batches of a dozen at a time. However, just like in CGT manufacturing, not all recipes can be significantly scaled up simply by linear ratios. The manufacturability of gene therapy vectors involves balancing multiple ingredients to ensure scalability of upstream (production) and downstream (purification) processes, along with reproducible yield and quality as well as regulatory compliance. Selecting and refining the vector backbone as well as optimization of the host strain and fermentation conditions has a significant impact on both efficacy and manufacturability. Importantly, these factors should be addressed together early on as any changes after the preclinical stage to optimize manufacturing may impact efficacy. By approaching therapeutic development with the end goal in mind (a scalable, GMP-compliant drug product), yields and efficacy of vectors can be significantly increased, as illustrated in Figure 5.
Figure 5. The CliniVec™ development approach improved yield and efficacy of a lentiviral (LV) vector with oversized payload (> 1.3kb larger).
-
Embedding safety
CGT vector safety is critical for successful clinical application. Drug developers must strictly control risks from antibiotic resistance, viral elements, and component toxicity/immunogenicity. Furthermore, impurities such as host cell DNA, residual proteins, empty capsids, etc. that are negligible at smaller scales can surface as a major problem at the manufacturing scale, necessitating extra purification steps that inevitably result in poor yields and high cost of goods (Figure 6). Selecting vector backbones that have been designed for clinical- and commercial-scale manufacturing, such as MiniVec™, or designing vectors to be scalable even during preclinical testing ensures that they meet the necessary safety standards at all scale levels and allows for smooth transition from research and validation to GMP manufacturing. This proactively mitigates the risk of regulatory non-compliance.
Figure 6. Designing CGT vectors to be scalable allows for seamless transition from laboratory to manufacturing production, resulting in less impurities in the final batch, increased effective yields, and lowered overall costs.
-
De-risking the timeline
Many CGT developers begin with a single vector candidate identified early in preclinical studies. The basis of this design is often selected considering efficacy in established cell lines that poorly reflect real patient biology. It feels efficient, right up until it fails preclinical toxicology or CMC guidelines, sending developers into that costly loop of redesign, revalidation, and comparability studies.
It’s the biotech version of “one cookie now or two cookies later.” The most successful CGT developers are those that invest time and embed scientific rigor from early in the product development lifecycle. They treat vector optimization as a core strategy (not an afterthought), make evidence-based decisions, and partner with experts who think the same way. This approach strikes the right balance between the shortest path to clinic and long-term product viability, ultimately saving time and costs.
Conclusion
In the high-stakes world of CGT, the transition from discovery to clinical application is often described as a leap over the infamous “valley of death” and for good reason: many promising therapies stall here, not necessarily due to flawed science, but due to insufficient rigor in early vector design, poor vector characterization, and limited scalability. At VectorBuilder, we advocate the critical importance of GVP principles throughout CGT development to enable a smoother and safer path to patients. Our expert CliniVec™ consultation service provides personalized support to help you navigate the intricacies of preclinical and clinical vector design. Stepping into the world of CGT development? Do it with confidence – reach out to the CliniVec™ team today! We have cookies.
Abbreviations
References
